Center Laboratories, Inc.
TTPEX:412329.90
TWD
0.00
(0.00%)
ISIN
TW0004123005
Return %
Stock
S&P 500
1Y
-9.22
14.20
3Y
-27.01
81.12
5Y
-25.24
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Jui Pao Hsu
- Full Time Employees
- 182
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 3-2, Yuanyuan Street Taipei TP Taiwan 115
- IPO Date
- Dec 18, 2002
- Website
- centerlab.com.tw
- Similar Companies
- Business
- Center Laboratories, Inc. (4123.TWO) operates as a biotechnology venture holdings group that develops, manufactures, and markets pharmaceuticals while investing in and incubating biotech firms across Asia Pacific. The company offers general medication pharmaceuticals, including antipyretic and analgesic agents, bronchodilators, anti-inflammatory preparations, anti-allergic agents, expectorants, narcotic and non-narcotic antitussives, gastrointestinal preparations, and other medicines; central nervous system medications for cerebrovascular disease, dementia, depression, schizophrenia, epilepsy, and Parkinson's disease; diabetes treatments targeting pancreatic beta cells; and specialty oral liquid formulations for infants, children, the elderly, and special care patients, holding a dominant 70% share of Taiwan's oral liquid drug market. It also engages in biotechnology investments, drug development, cell therapy, biopharmaceuticals, hydrogen energy, and dairy-related businesses through subsidiaries and portfolio companies. Center Laboratories maintains operations primarily in Taiwan with international reach in pharmaceuticals sales and biotech investments spanning China, Hong Kong, and Asia Pacific markets, targeting healthcare providers, patients, and biotech innovators. Founded in 1959 and headquartered in Taipei City, Taiwan, the company has undergone strategic transformations: in 1998 repositioning as a professional oral liquid pharmaceutical firm; in 2008 as a "Biotechnology Industrial Bank" via subsidiaries Bioengine Capital Inc. and Bioengine Technology Development Inc.; and in 2018 as the Center Ventures Group, a professional biotech venture holdings platform focused on operational revamps, mergers, acquisitions, and unicorn incubation exceeding NTD30 billion market caps. Recent developments include the 2022 full acquisition of Bioengine Technology Development Inc. and merger with Bioengine Capital Inc. to bolster venture capital positioning; 2023 investments in green hydrogen firm UMOE and Krisan Biotech for ADC CDMO services alongside Mycenax Biotech; 2024 board resolution for up to NTD10 billion purchase of investee Shuntian Pharmaceuticals (6535.TT) shares at NTD150-225 per share; and 2025 joint venture formation by portfolio company Ever Supreme Bio (Yongxin) with Japan's Alfresa-led firms for Alfenax Biologic Corporation, alongside strong portfolio performances from investees like Kacose Pharma and Shanghai Baoji Pharma. These moves underscore dual growth engines in core pharmaceuticals and emergent biotech investments, with Q3 2025 earnings reflecting NT$30.67 billion in financial asset gains and front-nine-month EPS of NT$3.52.